Monday, July 29, 2013
Cerespir Inc., of New York, disclosed positive interim clinical results from the Phase II trial by Chiesi Farmaceutici SpA, of Parma, Italy, testing CHF 5074, a first-in-class small-molecule microglia modulator, in patients with mild cognitive impairment (MCI).
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.